wellrank.ai
Sign In

My compounded semaglutide provider shut down. Where should I move my treatment?

ClaudeswitchingCollected Jul 19, 2026, 12:19 UTC

Verbatim response from Claude

Options for Continuing Semaglutide Treatment

Here are your best options, depending on your situation:

Licensed Telehealth Providers (Brand-Name GLP-1s)

  • Ro (ro.co) – Prescribes Wegovy/Ozempic; good patient support and insurance navigation help
  • Hims & Hers – Offers Wegovy prescriptions with competitive pricing programs
  • Noom Med – Combines medication with behavioral coaching
  • Found – Strong ongoing medical support and monitoring

Telehealth Focused on Affordability

  • Henry – Known for straightforward pricing and transparent costs
  • LifeMD – Works with insurance and offers savings programs

Important Considerations

Why compounding shut down: The FDA removed semaglutide from its shortage list, meaning most compounded versions are no longer legally permitted, so this will affect any compounding pharmacy route.

To reduce costs on brand-name:

  • Novo Nordisk's Patient Assistance Program (NovoCare) can significantly reduce Wegovy costs
  • Many providers help with prior authorization for insurance coverage

Practical Next Steps

  1. Request your records/prescription history from your previous provider
  2. Check if your insurance covers Wegovy or Ozempic
  3. Ask new providers about manufacturer savings cards

Would you like more detail on any of these options?

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.